Overview
Compare with Opko Health Inc., INSMED Inc or Legend Biotech, or pick any stock.
- TickerTGTX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersNew York City1
- Websitetgtherapeutics.com
- Incorporated inDE5
- Business address2 Gansevoort Street, 9Th Floor, New York, Ny 100145
- Filer categoryLarge accelerated filer5
- Legal formCorporation3
- LEI529900X21UKABN9NJ5293
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressc/o The Corporation Trust Company, Corporation Trust Center 1209 Orange St, 19801 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 23367563
See how the biggest companies compare on our leaderboards
Certain matters discussed in this Annual Report on Form 10-K contain forward-looking statements. All statements other than statements of historical facts may constitute forward-looking statements. We intend such forward-looking statements to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended (Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “co…6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
20.0%Operating margin7
72.6%Net margin7
87.3%Revenue growth, 20257
69.0%Return on equity7
0.38×Debt to equity7
-$25.0MFree cash flow7
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 97% of the revenue TG Therapeutics broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $92.0M | $313.7M | $606.9M |
| License | $141.7M | $15.3M | $9.4M |
| Royalty | $0 | $801.0K | $5.6M |
| Other Revenue | $1.5M | $1.8M | $3.6M |
| License revenue | $140.2M | $152.0K | $152.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue8¢$100.7M
- Research and development13¢$160.2M
- Selling, general and admin18¢$232.0M
- Income tax27¢$339.8M
- Profit35¢$447.2M
Out of $616.3M in revenue.7
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M |
| Cost of revenue | $100.7M | $38.5M | $14.1M |
| Noncash compensation | $16.6M | $11.2M | $13.0M |
| Other research and development | $143.6M | $83.1M | $63.2M |
| Total research and development | $160.2M | $94.3M | $76.2M |
| Noncash compensation | $48.1M | $31.4M | $24.9M |
| Other selling, general and administrative | $184.0M | $122.9M | $97.8M |
| Total selling, general and administrative | $232.0M | $154.3M | $122.7M |
| Total costs and expenses | $493.0M | $287.1M | $213.0M |
| Operating income | $123.3M | $41.9M | $20.6M |
| Interest expense | $26.7M | $24.0M | $12.6M |
| Other income | -$10.8M | -$7.7M | -$5.0M |
| Total other expense | $15.9M | $16.3M | $7.6M |
| Net income before taxes | $107.4M | $25.6M | $13.1M |
| Income tax benefit (expense) | $339.8M | -$2.2M | -$390.0K |
| Net income | $447.2M | $23.4M | $12.7M |
| Basic (in dollars per share) | $3.10 | $0.16 | $0.09 |
| Diluted (in dollars per share) | $2.77 | $0.15 | $0.09 |
| Basic (in shares) | 144.3M shares | 145.3M shares | 142.0M shares |
| Diluted (in shares) | 161.4M shares | 160.3M shares | 148.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $79.1M | $179.9M | $92.9M | |
| Short-term investment securities | $62.8M | $131.1M | ||
| Accounts receivable, net | $305.6M | $129.2M | ||
| Inventory | $125.6M | $110.5M | ||
| Other current assets | $57.6M | $15.7M | ||
| Total current assets | $630.8M | $566.4M | ||
| Restricted cash | $1.3M | $1.3M | ||
| Long-term investment securities | $59.1M | $808.0K | ||
| Right of use assets | $6.3M | $7.2M | ||
| Deferred tax assets | $348.0M | $0 | ||
| Long-term Inventory | $15.7M | $0 | ||
| Other noncurrent assets | $2.0M | $2.1M | ||
| Total assets | $1.1B | $577.7M | ||
| Accounts payable and accrued expenses | $107.5M | $58.3M | ||
| Other current liabilities | $2.1M | $4.6M | ||
| Lease liability current portion | $1.0M | $1.2M | ||
| Deferred revenue - current portion | $21.2M | $11.4M | ||
| Accrued compensation | $21.9M | $15.2M | ||
| Total current liabilities | $153.8M | $90.7M | ||
| Deferred revenue, non-current portion | $8.8M | $12.1M | ||
| Loan payable non-current | $245.6M | $244.4M | ||
| Lease liability non-current | $7.0M | $8.1M | ||
| Total liabilities | $415.2M | $355.3M | ||
| Common stock, $0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 158,849,596 and 156,204,159 shares issued, 155,305,953 and 155,836,256 shares outstanding at December 31, 2025 and December 31, 2024, respectively) | $159.0K | $156.0K | ||
| Additional paid-in capital | $1.8B | $1.8B | ||
| Treasury stock, at cost, 3,543,643 and 367,903 shares at December 31, 2025 and December 31, 2024 | -$100.2M | -$9.0M | ||
| Accumulated deficit | -$1.1B | -$1.5B | ||
| Total stockholders equity | $648.0M | $222.4M | $160.5M | $58.6M |
| Total liabilities and stockholders equity | $1.1B | $577.7M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 190.0M shares | 190.0M shares | ||
| Common stock, issued (in shares) | 158.8M shares | 156.2M shares | ||
| Common stock, outstanding (in shares) | 155.3M shares | 155.8M shares | ||
| Treasury stock, shares (in shares) | 3.5M shares | 367.9K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $79.1M | $179.9M | $92.9M | |
| Short-term investment securities | $62.8M | $131.1M | ||
| Accounts receivable, net | $305.6M | $129.2M | ||
| Inventory | $125.6M | $110.5M | ||
| Other current assets | $57.6M | $15.7M | ||
| Total current assets | $630.8M | $566.4M | ||
| Restricted cash | $1.3M | $1.3M | ||
| Long-term investment securities | $59.1M | $808.0K | ||
| Right of use assets | $6.3M | $7.2M | ||
| Deferred tax assets | $348.0M | $0 | ||
| Long-term Inventory | $15.7M | $0 | ||
| Other noncurrent assets | $2.0M | $2.1M | ||
| Total assets | $1.1B | $577.7M | ||
| Accounts payable and accrued expenses | $107.5M | $58.3M | ||
| Other current liabilities | $2.1M | $4.6M | ||
| Lease liability current portion | $1.0M | $1.2M | ||
| Deferred revenue - current portion | $21.2M | $11.4M | ||
| Accrued compensation | $21.9M | $15.2M | ||
| Total current liabilities | $153.8M | $90.7M | ||
| Deferred revenue, non-current portion | $8.8M | $12.1M | ||
| Loan payable non-current | $245.6M | $244.4M | ||
| Lease liability non-current | $7.0M | $8.1M | ||
| Total liabilities | $415.2M | $355.3M | ||
| Common stock, $0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 158,849,596 and 156,204,159 shares issued, 155,305,953 and 155,836,256 shares outstanding at December 31, 2025 and December 31, 2024, respectively) | $159.0K | $156.0K | ||
| Additional paid-in capital | $1.8B | $1.8B | ||
| Treasury stock, at cost, 3,543,643 and 367,903 shares at December 31, 2025 and December 31, 2024 | -$100.2M | -$9.0M | ||
| Accumulated deficit | -$1.1B | -$1.5B | ||
| Total stockholders equity | $648.0M | $222.4M | $160.5M | $58.6M |
| Total liabilities and stockholders equity | $1.1B | $577.7M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 190.0M shares | 190.0M shares | ||
| Common stock, issued (in shares) | 158.8M shares | 156.2M shares | ||
| Common stock, outstanding (in shares) | 155.3M shares | 155.8M shares | ||
| Treasury stock, shares (in shares) | 3.5M shares | 367.9K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | -$447.2M | -$23.4M | -$12.7M |
| Loss on extinguishment of debt | $0 | $4.6M | $0 |
| Noncash stock compensation expense | $64.7M | $42.5M | $37.9M |
| Depreciation and amortization | $59.0K | $68.0K | $211.0K |
| Amortization of discount on investment securities | -$3.8M | -$7.0M | -$2.2M |
| Amortization of debt issuance costs | $1.2M | $2.0M | $2.4M |
| Amortization of leasehold interest | $185.0K | $212.0K | $212.0K |
| Deferred income taxes | $348.0M | $0 | $0 |
| Noncash change in lease liability and right of use asset | $1.7M | $1.9M | $2.0M |
| Change in fair value of equity investments | $298.0K | $754.0K | $0 |
| Change in fair value of notes payable | $27.0K | $304.0K | $113.0K |
| Change in inventory reserve | $6.2M | $0 | $0 |
| Increase in inventory | -$33.5M | -$66.9M | -$36.9M |
| Increase in other current assets | -$42.4M | -$6.3M | -$2.8M |
| Increase in accounts receivable | -$176.4M | -$78.1M | -$51.1M |
| Increase in accounts payable and accrued expenses | $55.9M | $22.8M | $192.0K |
| Decrease in lease liabilities | -$2.1M | -$2.4M | -$2.4M |
| (Decrease) increase in other current liabilities | -$2.4M | $4.0M | $2.7M |
| Increase in deferred revenue | $6.4M | $17.5M | $5.7M |
| Net cash used in operating activities | -$24.8M | -$40.5M | -$31.4M |
| Proceeds from maturity of held-to-maturity securities | $237.5M | $310.9M | $96.2M |
| Investment in held-to-maturity securities | -$222.2M | -$310.5M | -$146.9M |
| Investment in equity investments | -$1.2M | -$1.4M | $0 |
| Purchases of Property, Plant and Equipment | -$214.0K | -$45.0K | $0 |
| Net cash provided by (used in) investing activities | $13.8M | -$1.0M | -$50.7M |
| Payment of loan payable | $0 | -$107.6M | $0 |
| Issuance of common stock, net | $0 | $0 | $46.3M |
| Proceeds from exercise of options | $1.5M | $914.0K | $1.5M |
| Proceeds from debt financings | $0 | $244.8M | $25.0M |
| Financing costs paid | $0 | -$889.0K | -$125.0K |
| Purchase of treasury stock | -$91.2M | -$8.8M | $0 |
| Net cash (used in) provided by financing activities | -$89.7M | $128.5M | $72.7M |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | -$100.7M | $87.0M | -$9.4M |
| Interest | $24.2M | $18.5M | $8.8M |
| Income taxes | $7.9M | $500.0K | $0 |
| Deferred Financing Costs | $0 | $0 | $1.2M |
| Warrants issued with debt financing | $0 | $0 | $595.0K |
No quarter-by-quarter statement was filed.
Corporate structure
TG Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of TG Therapeutics
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on TG Therapeutics, latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on TG Therapeutics, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
- State Street Corporation Filed SCHEDULE 13G on TG Therapeutics, latest Nov 10, 2025 (4 filings since Feb 3, 2023)
- BlackRock Filed SCHEDULE 13G/A on TG Therapeutics, latest Apr 30, 2025 (5 filings since Feb 1, 2022)
- Darwin Global Management, Ltd. Filed SC 13G/A on TG Therapeutics, latest Nov 14, 2024 (3 filings since Apr 3, 2023)
- FMR LLC Filed SC 13G/A on TG Therapeutics, latest Feb 9, 2023 (3 filings since Feb 9, 2022)
- TG Therapeutics New York, New York, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What TG Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Operating-lease assets (leased space) | $6.3M7 Dec 31, 2025 | $7.2M7 Dec 31, 2024 | −12.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $79.1M7 Dec 31, 2025 | $179.9M7 Dec 31, 2024 | −56.0% |
| Marketable securities, current | $62.8M7 Dec 31, 2025 | $131.1M7 Dec 31, 2024 | −52.1% |
| Long-term investments | $59.1M7 Dec 31, 2025 | $808.0K7 Dec 31, 2024 | +7218.8% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $125.6M7 Dec 31, 2025 | $110.5M7 Dec 31, 2024 | +13.7% |
| Raw materials | $28.2M11 Dec 31, 2024 | $6.6M11 Dec 31, 2023 | +327.7% |
| Work in process | $68.4M11 Dec 31, 2024 | $31.2M11 Dec 31, 2023 | +118.8% |
Properties, in its own words
We maintain corporate and executive space in Morrisville, North Carolina and New York, New York. We are also currently leasing small office space in Boca Raton, Florida.
We believe that our existing facilities are adequate to meet our current requirements. We do not own any real property.
Item 2 of the 10-K filed Feb 27, 2026.6
Leadership
Who has led TG Therapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerMichael S. Weiss Jan 2, 2013 to now15
- Chief executive officerDouglas Abel Jul 10, 2006 to Sep 15, 200816
- ChairMichael S. Weiss Jan 2, 2013 to Jan 2, 201315
- PresidentMichael S. Weiss Jan 4, 2017 to Aug 14, 202317
- PresidentDouglas Abel Jul 10, 2006 to Sep 15, 200816
- Chief financial officerSean A. Power Jan 9, 2012 to now18
- Chief financial officerMichael McGuinness Jul 11, 2006 to Mar 10, 201019
- Chief operating officerMichael McGuinness Mar 10, 2010 to Mar 10, 201020
Board members and other officers (18)
- OfficerMichael S. Weiss Jan 9, 2012 to Sep 1, 201621
- Board memberSagar Lonial Jul 2, 2020 to now22
- Board memberDaniel Hume Jun 17, 2015 to now23
- Board memberKenneth Hoberman Dec 23, 2014 to now24
- Board memberMichael S. Weiss Jan 9, 2012 to now21
- Board memberLaurence N. Charney Apr 26, 2012 to now25
- Board memberWilliam James Kennedy Apr 26, 2012 to Jun 24, 202026
- Board memberMark Schoenebaum Apr 27, 2012 to Jun 28, 201827
- Board memberYann Echelard Dec 7, 2012 to now28
- Board memberDavid Shimko Mar 22, 2010 to Mar 22, 201029
- Board memberMalcolm Morville Mar 22, 2010 to Mar 22, 201030
- Board memberRichard I. Steinhart Jan 31, 2007 to Mar 10, 201031
- Board memberJoan Pons Gimbert Feb 2, 2007 to Feb 2, 200732
- Board memberMalcolm Hoenlein Apr 27, 2007 to Mar 28, 200833
- Board memberNeil Herskowitz Jan 12, 2006 to Jun 10, 201434
- Board memberMichael Weiser Feb 2, 2006 to Sep 15, 200835
- Board memberTimothy McInerney Feb 2, 2006 to Mar 10, 201036
- Board memberDouglas Abel Jul 10, 2006 to Mar 10, 201016
Former names
Timeline
- Aug 3, 20268-K Results of operations37
- Jun 12, 20268-K Shareholder vote38
- Jun 3, 20268-K Other events39
- May 27, 20268-K Other events40
- May 6, 20268-K Results of operations41
- Mar 20, 20268-K Entered a material agreement; New debt or obligation42
- Feb 26, 20268-K Results of operations43
- Jan 13, 20268-K Regulation FD disclosure44
- Nov 3, 20258-K Results of operations45
- Aug 4, 20258-K Results of operations46
- Jun 13, 20258-K Shareholder vote47
- May 5, 20258-K Results of operations48
- Jan 2, 2013New chief executive Michael S. Weiss becomes CEO15
- Jul 10, 2006New chief executive Douglas Abel becomes CEO16
Calendar
Coming up
- Nov 2, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $2.43 a share, on Nov 3, 2025.49
When it reported results
- Aug 3, 2026Reported quarterly or annual results37
- May 6, 2026Reported quarterly or annual results41
- Feb 26, 2026Reported quarterly or annual results43
- Nov 3, 2025Reported quarterly or annual results45
- Aug 4, 2025Reported quarterly or annual results46
- May 5, 2025Reported quarterly or annual results48
- Mar 3, 2025Reported quarterly or annual results50
- Nov 4, 2024Reported quarterly or annual results51
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
175 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 35 major events, 58 insider forms, 22 large holders, 39 other. The latest 20:
- Sep 14, 20264 EDGAR
- Sep 10, 2026144 EDGAR
- Aug 7, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 3, 20268-K EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 12, 20268-K EDGAR
- Jun 3, 20268-K EDGAR
- May 27, 20268-K EDGAR
- May 6, 202610-Q EDGAR
- May 6, 20268-K EDGAR
- Apr 30, 2026DEF 14A EDGAR
- Apr 29, 2026SCHEDULE 13G EDGAR
- Mar 27, 2026SCHEDULE 13G/A EDGAR
- Mar 20, 20268-K EDGAR
- Feb 27, 202610-K EDGAR
The 175 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
24 open-market trades by officers, directors and large owners since October 2021: 2 buys and 22 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Charney Laurence NDirector | Sale | 5,000 | $54.96 | $274.8K | Form 4 |
| Nov 24, 2025 | Echelard YannDirector | Sale | 5,000 | $32.57 | $162.8K | Form 4 |
| Sep 11, 2025 | Lonial SagarDirector | Sale | 20,852 | $32.24 | $672.3K | Form 4 |
| Jun 13, 2025 | Echelard YannDirector | Sale | 10,000 | $36.94 | $369.4K | Form 4 |
| Jan 6, 2025 | Power Sean ACFO | Sale | 10,021 | $28.53 | $285.9K | Form 4 |
| Jan 3, 2025 | Power Sean ACFO | Sale | 11,337 | $30.29 | $343.4K | Form 4 |
| Nov 11, 2024 | Lonial SagarDirector | Sale | 5,000 | $30.44 | $152.2K | Form 4 |
| Nov 11, 2024 | Charney Laurence NDirector | Sale | 25,000 | $30.20 | $755.0K | Form 4 |
| Nov 5, 2024 | Echelard YannDirector | Sale | 20,000 | $24.48 | $489.6K | Form 4 |
| Jun 20, 2024 | Lonial SagarDirector | Sale | 16,348 | $16.87 | $275.8K | Form 4 |
| Jun 17, 2024 | Lonial SagarDirector | Sale | 9,585 | $16.39 | $157.1K | Form 4 |
| Mar 13, 2024 | Lonial SagarDirector | Sale | 5,000 | $15.94 | $79.7K | Form 4 |
| Mar 12, 2024 | Charney Laurence NDirector | Sale | 22,000 | $15.97 | $351.3K | Form 4 |
| Jan 5, 2024 | Charney Laurence NDirector | Sale | 17,500 | $19.03 | $333.0K | Form 4 |
| Jan 3, 2024 | Power Sean ACFO | Sale | 47,867 | $16.91 | $809.4K | Form 4 |
| Aug 11, 2023 | WEISS MICHAEL SCEO | Buy | 100,000 | $10.13 | $1.0M | Form 4 |
| Jun 23, 2023 | Lonial SagarDirector | Sale | 34,854 | $23.37 | $814.5K | Form 4 |
| Jun 2, 2023 | Power Sean ACFO | Sale | 73,647 | $26.70 | $2.0M | Form 4 |
| Jan 6, 2023 | Echelard YannDirector | Buy | 9,000 | $10.64 | $95.8K | Form 4 |
| Jan 4, 2023 | Charney Laurence NDirector | Sale | 30,000 | $11.10 | $333.0K | Form 4 |
All 24 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202652
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202653
- State Street CorporationSCHEDULE 13G, 4 filings Feb 3, 2023 to Nov 10, 202554
- BlackRockSCHEDULE 13G/A, 5 filings Feb 1, 2022 to Apr 30, 202555
- Darwin Global Management, Ltd.SC 13G/A, 3 filings Apr 3, 2023 to Nov 14, 202456
- FMR LLCSC 13G/A, 3 filings Feb 9, 2022 to Feb 9, 202357
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Michael S. Weiss | 60 | $875.0K | $25.6M58 |
| 2025 | Sean A. Power | 44 | $500.0K | $3.8M58 |
| 2024 | Chief Executive | $875.0K | $18.8M58 | |
| 2024 | Chief Financial OfficerTreasurer | $480.0K | $2.3M58 | |
| 2023 | Officer and President | $875.0K | $18.5M58 | |
| 2023 | and Corporate Secretary | $445.6K | $1.9M58 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 22,050,045 | $1.2B | 0.0% | −202,885 |
| Vanguard Portfolio Management LLC | 7,963,266 | $437.5M | 0.0% | −310,713 |
| State Street Corp | 7,786,471 | $427.8M | 0.0% | −863,295 |
| Vanguard Capital Management LLC | 6,149,403 | $337.8M | 0.0% | −453,855 |
| Geode Capital Management, LLC | 3,642,216 | $200.1M | 0.0% | +142,300 |
| D. E. Shaw & Co., Inc. | 3,400,808 | $186.8M | 0.1% | +2,810,761 |
| Soleus Capital Management, L.P. | 2,927,895 | $160.9M | 5.5% | −1,101,424 |
| Clearbridge Investments, LLC | 2,650,192 | $145.6M | 0.1% | −560,738 |
| Congress Asset Management Co | 2,600,123 | $142.9M | 0.9% | +432,042 |
| Two Sigma Investments, LP | 2,468,971 | $135.6M | 0.1% | +926,659 |
| Goldman Sachs Group Inc | 2,314,279 | $127.1M | 0.0% | +26,591 |
| Pictet Asset Management Holding SA | 1,785,951 | $98.1M | 0.1% | +38,578 |
| Jane Street Group, LLC | 1,752,646 | $96.3M | 0.1% | −289,023 |
| Nuveen, LLC | 1,625,876 | $89.3M | 0.0% | +178,798 |
| Morgan Stanley | 1,601,714 | $88.0M | 0.0% | +193,544 |
| Hood River Capital Management LLC | 1,600,510 | $87.9M | 0.6% | +31,339 |
| Northern Trust Corp | 1,537,059 | $84.4M | 0.0% | +94,480 |
| Charles Schwab Investment Management Inc | 1,313,103 | $72.1M | 0.0% | +18,048 |
| Bank Of America Corp /de/ | 1,309,788 | $72.0M | 0.0% | −151,514 |
| Dimensional Fund Advisors LP | 1,210,578 | $66.5M | 0.0% | +125,723 |
| Fmr LLC | 1,018,814 | $56.0M | 0.0% | +738,368 |
| Vanguard Fiduciary Trust Co | 961,750 | $52.8M | 0.0% | −6,916 |
| Barclays PLC | 957,848 | $52.6M | 0.0% | +841,191 |
| Bank of New York Mellon Corp | 900,482 | $49.5M | 0.0% | +13,177 |
| Bnp Paribas Financial Markets | 860,500 | $47.3M | 0.0% | −96,526 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How TG Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTG THERAPEUTICS, INC.2
- CIK0001001316
- Employer ID (EIN)36-38982696
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address2 Gansevoort Street, 9Th Floor, New York, NY 100142
- Phone(212) 554-44842
- Shares outstanding153,069,053 as of Aug 3, 202613
- Public float$2.5B as of Jun 30, 20256
- AuditorKPMG LLP, New York, NY PCAOB ID 185; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceJul 3, 19962
- Filings1,148 in all: 4 (296), 8-K (245), 10-Q (61), SC 13G/A (58), 424B3 (34), 10QSB (30), SC 13G (30), 3 (29)2
All 67 form types
DEF 14A (29), 5 (20), 10-K (19), 144 (18), UPLOAD (18), PRE 14A (17), CORRESP (16), 424B5 (15), S-3 (14), 10KSB (11), 8-K/A (11), EFFECT (11), NT 10-Q (10), S-8 (10), 10QSB/A (9), CT ORDER (9), DEFA14A (8), S-3/A (8), SC 13D/A (8), REGDEX (7), SB-2/A (6), 4/A (5), 10-K/A (4), 10-Q/A (4), POS AM (4), PREC14A (4), PX14A6G (4), S-1 (4), SC 13D (4), 424B1 (3), 8-A12B (3), PRRN14A (3), REGDEX/A (3), RW (3), S-3ASR (3), SB-2 (3), SCHEDULE 13G (3), SCHEDULE 13G/A (3), 10KSB/A (2), 3/A (2), ARS (2), D (2), D/A (2), DEF 14C (2), DEFR14A (2), NT 10-K (2), PRE 14C (2), S-1/A (2), 144/A (1), 25 (1), 25/A (1), 5/A (1), CERTAMX (1), CERTNAS (1), DEFC14A (1), DEFS14A (1), POS462B (1), PRER14A (1), PRER14C (1)
- Latest filingsAnnual report (10-K) Feb 27, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Aug 3, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 | TGTX | Nasdaq |
From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks TG Therapeutics names in Item 1A of its 10-K filed Feb 27, 2026: 74 risks under these headings, as written.6
- Risks Related to Commercialization
- If we obtain marketing approval from the U.S. Food and Drug Administration (FDA) or any comparable regulatory authority outside of the U.S. for a product candidate and do not achieve broad market acceptance among physicians, patients, healthcare payors, and the medical community, the revenues that we generate from product sales will be limited.
- We may be subject to limitations on the indicated uses or requirements to fulfill certain post-marketing requirements or commitments to the satisfaction of regulatory authorities or may be unable to maintain marketing approval for BRIUMVI or future products that we may bring to market.
- BRIUMVI, and any of our product candidates for which we in the future obtain marketing approval, may, after approval, be found to cause undesirable side effects that could result in significant negative consequences following commercialization.
- The incidence and prevalence for target patient populations of BRIUMVI and our other product candidates have not been established with precision. If the market opportunities for BRIUMVI and our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected.
- We face substantial competition, which may result in others commercializing drugs before or more successfully than we do, resulting in the reduction or elimination of our commercial opportunity.
- BRIUMVI, as well as any products that we are able to commercialize in the future, may become subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, which would harm our business.
- If we are unable to expand our commercialization operations, we may not be successful in commercializing BRIUMVI or any product candidate, if and when such product candidates are approved, and we may not be able to generate revenue.
- Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any drug candidates that we may develop.
- Any contracts that we enter into with government entities may involve future funding and compliance risks.
- Risks Related to Our Financial Position and Need for Additional Capital
- We have incurred substantial operating losses since our inception, and we may incur losses in the future.
The other 64 risks
- While we do not expect to need to raise additional capital, we may need to do so. If we are unable to raise capital, if needed, we may be required to delay, limit, reduce or eliminate some of our drug development programs or commercialization efforts.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates and occupy valuable management time and resources.
- Due to limited resources, we may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
- Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.
- We may not have cash available in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due.
- Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.
- Risks Related to Drug Development and Regulatory Approval
- If we are unable to maintain or obtain regulatory approval for our product or product candidates and ultimately cannot successfully commercialize our product or product candidates, or experience significant delays in doing so, our business will be materially harmed.
- Because results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance may not have favorable results in later clinical trials or receive regulatory approval. Moreover, interim, “top-line,” and preliminary data from our clinical trials that we announce or publish may change, or the perceived product profile may be negatively impacted, as more patient data or additional endpoints (including efficacy and safety) are analyzed.
- Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
- Biologics carry unique risks and uncertainties, which could have a negative impact on our business.
- Our product or product candidates may cause undesirable side effects or adverse events that could delay or prevent their regulatory approval or impact their availability and commercial potential after approval.
- Any products or product candidates we may advance through clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals.
- A Breakthrough Therapy or Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.
- We may seek orphan drug designation for some of our drug candidates. However, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
- We are conducting clinical trials and anticipate conducting additional clinical trials for our product and product candidates at sites outside the United States, and trials conducted in such locations or clinical trial activities in such locations may be impacted by political conditions, including international conflict.
- The FDA and other comparable regulatory authorities outside of the U.S. may not accept data from trials conducted in locations outside of their respective jurisdictions.
- Approval of one of our product candidates in the United States would not assure approval of that candidate in jurisdictions outside of the U.S.
- We have product candidates still under development and are also engaging manufacturing partners in commercial manufacturing activities, and as such clinical and commercial manufacturing site additions and process improvements implemented in the production of our product and product candidates may affect their timely delivery or quality.
- We may be unable to successfully develop, obtain regulatory approval for, or commercialize a subcutaneous formulation of our approved intravenous product, which could limit our ability to expand our market opportunity and patient reach.
- Risks Related to Governmental Regulation of Pharmaceutical Industry and Legal Compliance Matters
- We are subject to new legislation, regulatory proposals and third-party payor initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.
- Inadequate funding, government shutdowns, workforce reductions or other policy changes affecting the FDA, the SEC or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Some of our relationships with customers and third-party payors are subject to applicable fraud and abuse laws, false claims laws, transparency and disclosure laws, health information and security laws, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.
- If we violate applicable data privacy and security laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, reputation harm and the curtailment or restructuring of our operations.
- We, directly or through our third-party service providers, may adopt, use or incorporate artificial intelligence (AI) technology and capabilities into the information technology systems or software that we use in our business and operations. Defects in such AI technology or related security breaches, loss of data and other disruptions as well as changes in implementation standards and enforcement practices under a rapidly evolving regulatory framework for AI technology may adversely affect our business and operations and potentially expose us to increasing liability.
- If we fail to adequately understand and comply with the local laws and customs as we expand into new international markets, these operations may incur losses or otherwise adversely affect our business and results of operations.
- Any product for which we obtain marketing approval, including BRIUMVI, could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.
- If we or any of our contract manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business.
- Our research and development activities could be affected or delayed as a result of shortages in animal availability or possible restrictions on animal testing. Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products.
- Risks Related to Our Dependence on Third Parties
- We rely on third parties to generate clinical, preclinical and other data necessary to support the regulatory applications needed to conduct clinical trials and submit for marketing approval. We rely on third parties to help conduct our planned clinical trials. If these third parties do not perform their services as required, we may not be able to obtain regulatory approval for or commercialize our product or product candidates when expected or at all.
- We contract with third parties for the manufacture and testing of BRIUMVI for clinical and commercial supply, as well as for all development activities and clinical product supply for high concentration ublituximab and azer-cel, and we expect to continue to do so. This reliance on third parties increases the risk that we will not have sufficient quantities of our products or product candidates or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.
- The third parties upon whom we rely for the supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance, drug product, and other materials used in our drug candidates are our sole source of supply, and the loss or disruption of any of these suppliers could significantly harm our business.
- Because we have in-licensed BRIUMVI and our product candidates from third parties, any dispute with or non-performance by our licensors will adversely affect our ability to develop and commercialize the applicable product or product candidate.
- If conflicts arise between us and our future collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.
- We may seek to establish additional collaborations, and if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.
- Risks Related to Our Intellectual Property
- Our success depends upon our ability to obtain and protect our intellectual property and proprietary technologies. If the scope of our patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired. At the same time, if the scope of our patent protection is too broad, our competitors may challenge the validity and enforceability of our patents.
- Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- If we do not obtain patent term extensions under the Hatch-Waxman Act and similar foreign legislation extending the terms of our licensed patents and any future patents we may own, our business may be materially harmed.
- We may not be able to enforce our intellectual property rights throughout the world.
- We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.
- If we or our partners are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.
- We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.
- We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
- Risks Related to Our Business Organization and Governance, Strategy, Employees and Growth Management
- If we fail to attract and keep key management, commercial, and clinical development personnel, we may be unable to successfully develop or commercialize our product and product candidates.
- We will need to develop and expand our business, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.
- Certain anti-takeover provisions in our governing documents and Delaware law could make a third-party acquisition of us difficult. This could limit the price investors might be willing to pay in the future for our common stock.
- Our ability to utilize our net operating loss (NOL) carryforwards and certain other tax attributes may be limited.
- Certain of our executive officers, directors, principal stockholders and their affiliates maintain the ability to exercise significant influence over our company and all matters submitted to stockholders for approval.
- Our internal information technology systems, or those of our third-party CROs, CMOs, or other contractors, vendors, or consultants, are vulnerable to failures or security breaches, which could result in a material disruption of our drug candidates’ development programs and our commercialization of any products for which we receive regulatory approval.
- Unfavorable global economic conditions and changes in government regulations could adversely affect our business, financial condition or results of operations.
- Our employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.
- We may acquire businesses or drugs, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.
- We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
- Risks Related to Our Common Stock and Being a Publicly Traded Company
- Our stock price is, and we expect it to remain, volatile, which could limit investors’ ability to sell our stock at a profit.
- We are subject to risks related to corporate social responsibility and reputational matters.
- Climate change or legal, regulatory or market measures to address climate change may negatively affect our business, supply chain, results of operations, financial condition and growth prospects.
- Our ability to pay dividends, if any, are limited, and our stockholders may not receive any return on investment unless they sell their common stock.
- An active trading market for our common stock may not be sustained, and investors may not be able to resell their shares at or above the price they paid.
- If equity research analysts do not publish research or reports about our business or if they publish negative evaluations of or downgrade our common stock, the price of our common stock could decline.
- We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.
- Volatility in the price of our common stock may subject us to securities and shareholder derivative litigation, which could cause us to incur substantial costs and divert management’s attention, financial resources and other company assets.
- Future sales of our common stock, including by us or our directors and executive officers or shares issued upon the exercise of currently outstanding options, could cause our stock price to decline.
Legal proceedings
We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal proceedings.
The opening of Item 3, Legal Proceedings.6
Links
- Websitetgtherapeutics.com1
- X (Twitter)x.com/TGTherapeutics1
- LinkedInwww.linkedin.com/company/tg-therapeutics1
- WikidataQ106301317
- SEC EDGARCIK 1001316
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataTG Therapeutics on Wikidata
- 2SEC EDGARTG Therapeutics filings on SEC EDGAR
- 3
- 4Company websiteTG Therapeutics logo
- 5SEC EDGARTG Therapeutics filings on SEC EDGAR
- 6
- 7SEC EDGARTG Therapeutics 10-K for fiscal 2025
- 8SEC EDGARTG Therapeutics 10-K for fiscal 2019
- 9SEC EDGARTG Therapeutics 10-K for fiscal 2020
- 10SEC EDGARTG Therapeutics 10-K for fiscal 2021
- 11SEC EDGARTG Therapeutics 10-K for fiscal 2022
- 12SEC EDGARTG Therapeutics 10-Q for fiscal 2026
- 13SEC EDGARTG Therapeutics 10-Q for fiscal 2026
- 14SEC EDGARTG Therapeutics 10-K for fiscal 2019
- 15
- 16
- 17SEC EDGARMichael S. Weiss, President
- 18
- 19
- 20
- 21SEC EDGARMichael S. Weiss, Officer
- 22SEC EDGARSagar Lonial, Board member
- 23SEC EDGARDaniel Hume, Board member
- 24SEC EDGARKenneth Hoberman, Board member
- 25SEC EDGARLaurence N. Charney, Board member
- 26SEC EDGARWilliam James Kennedy, Board member
- 27SEC EDGARMark Schoenebaum, Board member
- 28SEC EDGARYann Echelard, Board member
- 29SEC EDGARDavid Shimko, Board member
- 30SEC EDGARMalcolm Morville, Board member
- 31SEC EDGARRichard I. Steinhart, Board member
- 32SEC EDGARJoan Pons Gimbert, Board member
- 33SEC EDGARMalcolm Hoenlein, Board member
- 34SEC EDGARNeil Herskowitz, Board member
- 35SEC EDGARMichael Weiser, Board member
- 36SEC EDGARTimothy McInerney, Board member
- 37SEC EDGARResults of operations
- 38SEC EDGARShareholder vote
- 39SEC EDGAROther events
- 40SEC EDGAROther events
- 41SEC EDGARResults of operations
- 42
- 43SEC EDGARResults of operations
- 44SEC EDGARRegulation FD disclosure
- 45SEC EDGARResults of operations
- 46SEC EDGARResults of operations
- 47SEC EDGARShareholder vote
- 48SEC EDGARResults of operations
- 49NasdaqNasdaq calendar
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57SEC EDGARFMR LLC SC 13G/A on TG Therapeutics
- 58